Why Global Structuring and Transfer Pricing Matter for Life Sciences Companies 

The life sciences industry is characterized by high-value intellectual property (“IP”), extensive research and development (R&D), complex regulatory environments, and global supply chains. Life sciences companies are increasingly global from day one where R&D is performed in one country, clinical trials in others, IP held centrally, and manufacturing and commercialization is performed elsewhere. These unique attributes create opportunity, but it also creates tax risk if global structuring and transfer pricing are not addressed early and deliberately. Multinational enterprises (MNEs) must navigate the intricate balance of incentivizing innovation, managing regulatory compliance, and ensuring arm’s length remuneration for intercompany transactions involving drug development, manufacturing, and distribution activities. 

We continue to see tax, IP, and investor issues arise, not because companies were aggressive, but because their structure did not keep pace with how the business actually operated. 

IP is the Core Asset as well as the Core Risk 

For most life sciences companies, intangible assets represent the majority of enterprise value. Patents, proprietary drug formulations, clinical trial data, regulatory approvals, and brand names are often the most valuable assets. The ability to successfully market and distribute drugs, often requiring significant local market knowledge and investment, also create valuable marketing intangibles. Tax authorities are focused less on where these intangible assets are legally owned and more on where they are developed, controlled, and economically exploited, since that is central to profit allocation. 

If the people making R&D decisions, managing clinical strategy, or assuming development risk sit in one country while IP is housed elsewhere without sufficient substance, authorities may challenge: 

These challenges often surface years later when products succeed, and profits finally materialize. 

Transfer Pricing Failures Lead to Multiple Tax Claims 

A common issue in life sciences audits is two or more tax authorities asserting the right to tax the same income. This typically stems from: 

Once profits increase, tax authorities scrutinize prior year losses and recharacterize arrangements retroactively. Relief through treaty processes can be slow, uncertain, and expensive. 

Investors Care More Than Many Companies Expect 

From early stage venture rounds through exit transactions, investors focus heavily on: 

Weak structuring can reduce valuation, delay transactions, or result in escrow and indemnity demands. In some cases, it becomes a dealbreaker. Well-planned structuring, by contrast, supports a clear value creation narrative that aligns tax outcomes with operational reality. 

Regulatory and Tax Positions Must Align 

The global tax and regulatory environment is rapidly evolving, with significant implications for life sciences companies. One major development is the Organization for Economic Co-operation and Development’s (OECD) Pillar Two framework, which introduces a global minimum tax for large Multinational Enterprises. At the same time, tariffs on critical inputs or finished goods are disrupting global R&D, manufacturing, and distribution. Domestic tax measures, such as the U.S. Base Erosion and Anti‑Abuse Tax (BEAT), can further pressure centralized operating models by operating as a minimum tax that may increase liability when significant deductible payments are made to foreign related parties (for example, royalties, interest, and certain services). 

Life sciences companies operate under significant regulatory oversight. Tax structures that ignore regulatory accountability, particularly in manufacturing, quality control, or clinical oversight, are increasingly vulnerable. Authorities now share information across agencies, making inconsistencies easier to identify and harder to defend. Additionally, tax authorities around the world are increasingly contentious, often recharacterizing transactions or demanding higher local remuneration for “value-creating” activities. 

Waiting to “Fix It Later” Is Usually More Expensive 

Many companies defer global structuring until revenue or commercialization. By then, the cost of change is often much higher due to: 

Drug discovery and development involve significant upfront investment, long timelines, and high failure rates. Early planning, when valuations are lower and operations are still evolving, provides materially more flexibility. Managing this requires a globally consistent narrative and, often, Advance Pricing Agreements (APAs) to gain multi-year certainty from tax authorities.

Final Thoughts

Global structuring and transfer pricing are not academic tax exercises for life sciences companies. They directly affect IP protection, investor confidence, audit risk, and long-term enterprise value. Due to increased IRS scrutiny and shifting global tax laws, transfer pricing is a critical tax risk for life sciences companies. Because these companies rely heavily on high-value IP and global supply chains, the intercompany transactions are prime targets for audits. Companies that align structure, substance, and transfer pricing early are better positioned to scale, raise capital, and exit successfully without surprises from tax authorities later. 

If your company is navigating global expansion, IP planning, or transfer pricing considerations, now is the time to ensure your structure aligns with your operational reality. A proactive assessment can help identify risks, support investor readiness and position your business for sustainable growth. Connect with our team to discuss how a tailored global structuring and transfer pricing strategy can support your long-term objectives.